Beta-Carotene
Catalog No: CFN98117
Beta Carotene is an organic compound and classified as a terpenoid. It is a precursor (inactive form) of vitamin A. Beta-Carotene has antioxidant activity, anti-cancer, and antiapoptotic activities, it has protective effects against gamma-radiation-induced in vivo chromosomal damage. Dietary supplementation of carotenoids may act as moderate hypocholesterolemic agents, secondary to their inhibitory effect on macrophage 3-hydroxy-3-methyl glutaryl coenzyme A (HMGCoA) reductase, the rate limiting enzyme in cholesterol synthesis.
Fargesin
Catalog No: CFN98174
Fargesin has anti-inflammatory, anti-cancer, antihypertensive , and anti-bone-resorbing effects, it is widely used in the treatment of managing rhinitis, inflammation, histamine, sinusitis, and headache. Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice by activating Akt and AMPK in WAT. It as a potential β1 adrenergic receptor antagonist protects the hearts against ischemia/reperfusion injury in rats via attenuating oxidative stress and apoptosis.
Oleuropein
Catalog No: CFN98416
Oleuropein exhibits anti-ischemic, antioxidative, hypolipidemic, in vitro antimycoplasmal , anti-inflammatory, and anti-cancer effects., it also may be helpful in the prevention of diabetic complications associated with oxidative stress. Oleuropein prevents oxidative myocardial injury induced by ischemia and reperfusion, and reduces viremia in duck hepatitis B virus (DHBV)-infected ducks. Oleuropein reduces TLR and MAPK signaling.
Cajanin
Catalog No: CFN98419
Cajanin has potential hypolipidemic effects,possibly via up-regulating the ABCA1 protein expression,subsequently resulting in increased macrophage cholesterol efflux and RCT, it can significantly improve basal glucose uptake in HepG2 cells, its improving effect is concentration dependent, it exhibits effects stronger than that of rosiglitazone, which has been used as an antidiabetic drug. Cajanin has strong mitogenic as well as differentiation-promoting effects on osteoblasts that involved subsequent activation of MEK-Erk and Akt pathways.
